DaVita Inc. DVA has been gaining from its business model. The optimism, led by a solid fourth-quarter 2025 performance and ...

In the latest close session, DaVita HealthCare (DVA) was up +1.51% at $150.68. The stock exceeded the S&P 500, which registered a gain of 0.62% for the day. Elsewhere, the Dow gained 0.58%, while the ...

DaVita is an attractive company at the right price. The company's fundamentals, including its credit rating, lack of a yield, ...

Shares of kidney dialysis treatment company DaVita understandably struggled in 2025. Its most recent quarterly report and guidance for the year ahead, however, were both better than anticipated. While ...

Shares of DaVita (NYSE: DVA) climbed 8.6% on Wednesday after the dialysis services company announced strong fourth-quarter 2023 results. DaVita's quarterly revenue grew 7.8% year over year to $3.15 ...

DaVita is back in the spotlight as analysts recalibrate their price targets, with some boosting estimates by as much as $30 while the core Fair Value sits at $151.71. These shifts are being driven ...

We recently compiled a list titled Buffett Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we will look at where DaVita Inc. (NYSE:DVA) ranks among the top 10 stocks in Buffet’s ...

DaVita Inc. closed 5.70% short of its 52-week high of $159.42, which the company achieved on March 2nd.

Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of ...